Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Melero, I. (I.), Castanon Alvarez, E. (E.), Mau-Sorensen, M. (M.), U. Lassen (Ulrik), M.P. Lolkema (Martijn), Robbrecht, D.G. (D. G.), C. Gomez-Roca (Carlos), Martin-Liberal, J. (J.), J. Tabernero (Josep), Ros, W. (W.), et al. J.H.M. Schellens (Jan)

2018-10-01

Annals of Oncology , Volume 29 p. viii134- viii135

Additional Metadata
Persistent URL	doi.org/10.1093/annonc/mdy279.400, hdl.handle.net/1765/125541
Journal	Annals of Oncology
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Melero, I. (I.), Castanon Alvarez, E. (E.), Mau-Sorensen, M. (M.), Lassen, U., Lolkema, M., Robbrecht, D.G. (D. G.), … Schellens, J. (2018). Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). Annals of Oncology, 29, viii134–viii135. doi:10.1093/annonc/mdy279.400

Publication